Your session is about to expire
← Back to Search
Capmatinib for Non-Small Cell Lung Cancer (Geometry-N Trial)
Geometry-N Trial Summary
This trial will test if adding the drug capmatinib to surgery, chemotherapy, and radiation can improve outcomes for people with early- to mid-stage non-small cell lung cancer that has MET mutations or high MET amplification.
Geometry-N Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowGeometry-N Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Geometry-N Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung cancer is at a specific stage and has been confirmed by a tissue test.I have or had lung inflammation or scarring.My cancer has MET exon 14 mutations or high MET amplification.My cancer cannot be removed by surgery and I've had brain scans to check for cancer spread.I haven't had cancer treatments like chemotherapy for my lung cancer in the last 3 years.I am scheduled for surgery within 2 weeks after my last pre-surgery treatment.I have never been treated with MET inhibitors or HGF-targeting therapy.I have not had major surgery in the last 4 weeks or still recovering from one.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
How many individuals are currently participating in this investigation?
"This medical trial needs 38 volunteers that meet the eligibility requirements. UCLA Oncology Hematology in La Jolla and Dana Farber Cancer Center in Boston are two of several available locations for participation."
Has capmatinib been officially endorsed by the FDA?
"Capmatinib has been assigned a score of 2 as it is currently undergoing Phase 2 trials, which have provided some assurance that the drug is safe but no data to prove its efficacy."
How many health care facilities are participating in this experiment?
"There are 8 participating sites in this trial, e.g., UCLA Oncology Hematology in La Jolla, Dana Farber Cancer Center in Boston, and University of Michigan Health System in Ann Arbor. Additionally there are 5 other establishments contributing to the study."
What other exploratory data has been gathered regarding capmatinib?
"Research into capmatinib has been ongoing since 2013, with 13 completed clinical trials and 15 more currently underway. Much of the current research is taking place at a Novartis Investigative Site in La Jolla, California."
Is recruitment for this trial currently open?
"The information hosted on clinicaltrials.gov shows that this trial is currently in the process of recruiting patients. This clinical experiment was first launched on August 10th 2022 and has seen its most recent update occur on October 5th 2022."
Are individuals under the age of thirty-five considered viable candidates for this experiment?
"This clinical trial is available for individuals aged between 18 and 90. Alternatively, there are 23 trials specifically targeting minors and 1428 studies with a primary focus on those 65 years old or above."
Is this the inaugural investigation of its kind?
"Researching capmatinib has been underway since 2013, when Novartis Pharmaceuticals ran the first study with 38 participants. This was followed by Phase 2 drug approval and now there are 15 active experiments involving this medication across 130 cities in 39 nations."
Do I meet the qualifications to join this research trial?
"This trial is open to 38 individuals diagnosed with non-small cell lung cancer who are between 18 and 90 years of age. To qualify, prospective participants must either possess MET exon 14 mutations or display high level MET amplification, in addition to being eligible for surgery within two weeks after the final dose of preoperative study medication."
Share this study with friends
Copy Link
Messenger